Filing Flows › ClearPoint Neuro (CLPT) › Q1 2025
ClearPoint Neuro (CLPT) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 13, 2025
ClearPoint Neuro (CLPT) reported revenue of $8.5M for the first quarter 2025 (Q1 2025), +11% from a year earlier and +9% from the quarter before. Operating margin was -72.6%, net loss $6.0M (71.0% of revenue).
ClearPoint Neuro, Q1 2025: revenue $8.5M (+11% year over year), operating margin -72.6%, net loss $6.0M, operating cash flow −$6.2M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $8.5M | +9% | +11% |
| Operating profit | −$6.2M | — | — |
| Net earnings | −$6.0M | — | — |
| Operating cash flow | −$6.2M | — | — |
What changed
Revenue was $8.5M in Q1 2025, up 11% year over year and up 9% from the previous quarter. Neurosurgery Navigation and Therapy Disposable Products was the largest line at 39% of revenue. Neurosurgery Navigation and Therapy Disposable Products added $1.4M year over year (up 70%), 160% of the total change. Capital Equipment and Software Systems and Software Products declined 80%.
Gross margin was 60.5%, up 1.2 points from a year earlier. Operating costs exceeded revenue by $6.2M, an operating margin of -72.6%. Operating expenses grew 29% against revenue growth of 11%. The fastest-growing cost line was SG&A (+44%). The quarter ended with a net loss of $6.0M, wider than the previous quarter's $5.4M loss.
Operating cash flow was −$6.2M. Non-cash charges added back $103K of depreciation and amortization and $1.9M of share-based compensation. Working capital and other items used $2.2M. Capital expenditures of $183K exceeded it, leaving free cash flow of −$6.4M.
Questions
What was ClearPoint Neuro's revenue in the first quarter 2025?
ClearPoint Neuro (CLPT) reported revenue of $8.5M for the first quarter 2025 (Q1 2025), +11% from a year earlier and +9% from the quarter before.
Was ClearPoint Neuro profitable in the first quarter 2025?
Operating loss was $6.2M (-72.6% of revenue) and net loss $6.0M.
Source: ClearPoint Neuro 10-Q on SEC EDGAR.